AZN Oct 2023 65.000 call
| Previous close | 9.90 |
| Open | 9.95 |
| Bid | 9.50 |
| Ask | 10.15 |
| Strike | 65.00 |
| Expiry date | 2023-10-20 |
| Day's range | 9.90 - 9.95 |
| Contract range | N/A |
| Volume | |
| Open interest | 504 |
- Financial Times
AstraZeneca defies geopolitics to bet on China
AstraZeneca’s chief executive returned from a recent trip to China exuberant about an “explosion” of biotech companies in the country and the potential for his business to deliver drugs discovered there to the world. Pascal Soriot said the market was “completely open” for pharma investment. “It’s hard to not be impressed by the progress that has been made in China over the last few years,” he added on a press call in April.
Business WireLYNPARZA® (olaparib) and IMFINZI® (durvalumab) combination reduced risk of disease progression or death by 37% vs. chemotherapy and bevacizumab in patients with advanced ovarian cancer without tumor BRCA mutations in the DUO-O Phase III trial
WILMINGTON, Del., June 03, 2023--Positive results from a planned interim analysis of the DUO-O Phase III trial showed that treatment with a combination of LYNPARZA® (olaparib), IMFINZI® (durvalumab), chemotherapy and bevacizumab demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus chemotherapy plus bevacizumab (control arm) in newly diagnosed patients with advanced high-grade epithelial ovarian cancer without tumor BRCA mutation
Business WireIMFINZI® (durvalumab) plus chemotherapy significantly improved pathologic complete response in gastric and gastroesophageal junction cancers in MATTERHORN Phase III trial
WILMINGTON, Del., June 02, 2023--Positive high-level results from a planned interim analysis of the MATTERHORN Phase III trial showed treatment with AstraZeneca’s IMFINZI® (durvalumab) added to standard-of-care FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) neoadjuvant (before surgery) chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the key secondary endpoint of pathologic complete response (pCR) versus neoadjuvant chemotherapy alone fo
ZacksTop Research Reports for Exxon Mobil, AstraZeneca & Netflix
Today's Research Daily features new research reports on 16 major stocks, including Exxon Mobil Corporation (XOM), AstraZeneca PLC (AZN) and Netflix, Inc. (NFLX).
ZacksFDA Expands AstraZeneca (AZN) Lynparza Label in Prostate Cancer
Following FDA's label-expansion approval, AstraZeneca's (AZN)/Merck's (MRK) Lynparza is the first PARP inhibitor approved in combination with a new hormonal agent in mCRPC.
ZacksIonis (IONS) Posts Two-Year Upbeat Data From HAE Drug Study
Data from a mid-stage study shows that treatment with Ionis' (IONS) donidalorsen over a two-year period resulted in consistent and sustained protection from HAE attacks.
ZacksPharma Stock Roundup: FDA Okays PFE RSV Jab for Elderly, AZN Ends Brazikumab Studies
FDA approves Pfizer's (PFE) RSV vaccine for older adults and AstraZeneca (AZN) and Merck's (MRK) Lynparza for BRCA-mutated metastatic castration-resistant prostate cancer
ZacksHere's Why Astrazeneca (AZN) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Motley Fool3 Nasdaq 100 Stocks That Are Surefire Buys in June
These phenomenal businesses have the tools and intangibles to make patient shareholders a lot richer.
ZacksAstraZeneca (AZN) Discontinues Brazikumab Development
AstraZeneca (AZN) announces its decision to discontinue the development of brazikumab for all indications under its inflammatory bowel disease program.
Business WireLYNPARZA® (olaparib) plus abiraterone approved in the US for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer
WILMINGTON, Del., June 01, 2023--AstraZeneca and Merck & Co., Inc’s, known as MSD outside the US and Canada, LYNPARZA® (olaparib) in combination with abiraterone and prednisone or prednisolone has been approved in the US for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC).
- Zacks
AstraZeneca (AZN) Drug Combo Meets Endometrial Cancer Study Goal
AstraZeneca (AZN) reports statistically significant results from a late-stage study evaluating the combination of Imfinzi and Lynparza in patients with advanced endometrial cancer.
Motley FoolWant to Grow Richer? These Stocks Have Doubled in the Past 5 Years
Shares of AstraZeneca (NASDAQ: AZN) and Merck (NYSE: MRK) have both more than doubled over the last five years. With a $228 billion market capitalization, AstraZeneca is the sixth-largest pharmaceutical company in the world and the second-biggest international-based drugmaker behind Novartis (NYSE: NVS). As you'd guess would be the case for a major player in the pharmaceutical industry, the British drugmaker possesses a remarkable product portfolio.
Business WireIMFINZI® (durvalumab) plus LYNPARZA® (olaparib) and IMFINZI alone both significantly improved progression-free survival in advanced endometrial cancer when added to chemotherapy
WILMINGTON, Del., May 26, 2023--Positive high-level results from the DUO-E Phase III trial showed IMFINZI® (durvalumab) in combination with platinum-based chemotherapy followed by either IMFINZI plus LYNPARZA® (olaparib) or IMFINZI alone as maintenance therapy both demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to standard-of-care chemotherapy alone in patients with newly diagnosed advanced or recurrent endometrial cance
Business WireAstraZeneca will highlight momentum of practice-changing cancer medicines across its robust pipeline at ASCO 2023
WILMINGTON, Del., May 25, 2023--AstraZeneca advances its ambition to revolutionize cancer care with new data across its industry-leading portfolio of cancer medicines at the American Society of Clinical Oncology (ASCO) Annual Meeting, June 2 to 6, 2023.
Business WireNew AstraZeneca Data Presented at ATS 2023 Strengthen the Body of Evidence Supporting Early Intervention With BREZTRI in COPD
WILMINGTON, Del., May 23, 2023--Results from the EROS real-world retrospective study showed that initiating fixed-dose triple-combination therapy BREZTRI AEROSPHERE® (budesonide/glycopyrronium/formoterol fumarate) within 30 days of a qualifying moderate or severe exacerbation in patients with COPD (chronic obstructive pulmonary disease) is associated with a decreased risk of future exacerbations by 24% vs. delaying treatment by one to six months, and by 34% vs. delaying treatment six months to o
ZacksWhy Astrazeneca (AZN) is a Great Dividend Stock Right Now
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Astrazeneca (AZN) have what it takes? Let's find out.
Business WireTAGRISSO® (osimertinib) plus chemotherapy demonstrated strong improvement in progression-free survival for patients with EGFR-mutated advanced lung cancer in FLAURA2 Phase III trial
WILMINGTON, Del., May 17, 2023--Positive high-level results from the FLAURA2 Phase III trial showed AstraZeneca’s TAGRISSO® (osimertinib) in combination with chemotherapy demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to TAGRISSO alone for patients with locally advanced (Stage IIIB-IIIC) or metastatic (Stage IV) epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC).
Motley FoolIs AstraZeneca Stock a Buy for Growth Investors?
Just 14% of drugs in development (according to a 2018 study) ever make it to market, so investing in pharmaceuticals is a bit of a shot in the dark. This is why I'd advise most investors to consider only the most dominant and established pharmaceutical companies for their portfolios. British drugmaker AstraZeneca (NASDAQ: AZN) is one such company.
- Zacks
Pharma Stock Roundup: BAYRY Mixed Q1 Results, AZN, RHHBY Regulatory/Pipeline Updates
Bayer (BAYRY) announces mixed Q1 results. AstraZeneca's (AZN) Ultomiris gets approval for a new rare disease indication in the EU.
Business WireFARXIGA extended in the US to reduce risk of cardiovascular death and hospitalization for heart failure to a broader range of patients
WILMINGTON, Del., May 09, 2023--AstraZeneca’s FARXIGA (dapagliflozin) has been approved in the US to reduce the risk of cardiovascular (CV) death, hospitalization for heart failure (hHF) and urgent heart failure (HF) visits in adults with HF. The approval by the Food and Drug Administration (FDA) was based on positive results from the DELIVER Phase III trial.1 FARXIGA was previously approved in the US for adults with HF with reduced ejection fraction (HFrEF).
ZacksWhy Astrazeneca (AZN) is a Top Dividend Stock for Your Portfolio
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Astrazeneca (AZN) have what it takes? Let's find out.
Motley FoolAstraZeneca Plc (AZN) Q1 2023 Earnings Call Transcript
Before I hand over to AstraZeneca, I'd like to read the safe harbor statement. The company intends to utilize the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Participants on this call may make forward-looking statements with respect to the operations and financial performance of AstraZeneca.
- Zacks
Pharma Stock Roundup: MRK & Others Post Q1 Results, LLY Drug Shines in Obesity Study
Merck (MRK), Eli Lilly (LLY), AstraZeneca (AZN) and others report first-quarter results. J&J (JNJ) provides an update on the IPO of its Consumer Health segment, Kenvue.
ZacksAmgen (AMGN) Q1 Earnings Beat Estimates, 2023 View Raised
Amgen (AMGN) beats estimates for earnings but misses the same for sales. It raises its earnings and sales guidance for 2023.